Squarepoint’s Altimmune ALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $55.8K | Sell |
18,126
-16,823
| -48% | -$71.4K | ﹤0.01% | 4132 |
|
|
2025
Q4 | $126K | Sell |
34,949
-549,747
| -94% | -$2.4M | ﹤0.01% | 3994 |
|
|
2025
Q3 | $2.2M | Buy |
+584,696
| New | +$2.26M | ﹤0.01% | 2014 |
|
|
2025
Q2 | – | Sell |
-133,885
| Closed | -$669K | – | 4447 |
|
|
2025
Q1 | $669K | Buy |
133,885
+119,179
| +810% | +$755K | ﹤0.01% | 3025 |
|
|
2024
Q4 | $106K | Sell |
14,706
-46,982
| -76% | -$359K | ﹤0.01% | 4686 |
|
|
2024
Q3 | $379K | Buy |
+61,688
| New | +$418K | ﹤0.01% | 3307 |
|
|
2024
Q2 | – | Sell |
-13,178
| Closed | -$134K | – | 4012 |
|
|
2024
Q1 | $134K | Sell |
13,178
-99,595
| -88% | -$1.01M | ﹤0.01% | 3730 |
|
|
2023
Q4 | $1.27M | Buy |
+112,773
| New | +$471K | ﹤0.01% | 2352 |
|
|
2023
Q3 | – | Sell |
-139,911
| Closed | -$494K | – | 3746 |
|
|
2023
Q2 | $494K | Sell |
139,911
-74,353
| -35% | -$334K | ﹤0.01% | 2626 |
|
|
2023
Q1 | $904K | Buy |
+214,264
| New | +$2.55M | ﹤0.01% | 1963 |
|
|
2022
Q3 | – | Sell |
-28,133
| Closed | -$329K | – | 2953 |
|
|
2022
Q2 | $329K | Sell |
28,133
-66,494
| -70% | -$410K | ﹤0.01% | 2246 |
|
|
2022
Q1 | $576K | Buy |
94,627
+80,246
| +558% | +$591K | ﹤0.01% | 1927 |
|
|
2021
Q4 | $132K | Sell |
14,381
-46,227
| -76% | -$491K | ﹤0.01% | 2849 |
|
|
2021
Q3 | $685K | Buy |
60,608
+50,256
| +485% | +$611K | ﹤0.01% | 1784 |
|
|
2021
Q2 | $102K | Buy |
+10,352
| New | +$142K | ﹤0.01% | 3008 |
|
|
2020
Q4 | – | Sell |
-20,427
| Closed | -$270K | – | 2875 |
|
|
2020
Q3 | $270K | Buy |
+20,427
| New | +$408K | ﹤0.01% | 1879 |
|
|
2019
Q4 | – | Sell |
-11,248
| Closed | -$22K | – | 2456 |
|
|
2019
Q3 | $22K | Sell |
11,248
-10,272
| -48% | -$22.8K | ﹤0.01% | 2271 |
|
|
2019
Q2 | $51K | Sell |
21,520
-12,346
| -36% | -$33K | ﹤0.01% | 2278 |
|
|
2019
Q1 | $98K | Buy |
+33,866
| New | +$101K | ﹤0.01% | 2039 |
|
|
2017
Q4 | – | Sell |
-710
| Closed | -$49K | – | 2059 |
|
|
2017
Q3 | $49K | Buy |
+710
| New | +$52.9K | ﹤0.01% | 1561 |
|
|
2017
Q1 | – | Sell |
-371
| Closed | -$362K | – | 1500 |
|
|
2016
Q4 | $362K | Buy |
371
+329
| +783% | +$295K | 0.01% | 1029 |
|
|
2016
Q3 | $37K | Buy |
+42
| New | +$32.9K | ﹤0.01% | 976 |
|
Other funds holding ALT
VCM
VPM
N
Squarepoint's ALT Position: Q1 2026 in Review
Squarepoint reduced its Altimmune (ALT) stake by 48% in Q1 2026, selling an estimated $71.4K and leaving 18,126 shares worth $55.8K. The position accounts for ﹤0.01% of the portfolio, ranked #4132.
Squarepoint first reported a position in ALT in Q3 2016 and has held it in 22 quarters since. The position peaked at $2.2M in Q3 2025. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.
- Squarepoint held 18,126 shares of Altimmune worth $55.8K as of Q1 2026.
- Squarepoint sold 16,823 Altimmune shares in Q1 2026, an estimated $71.4K.
- Altimmune made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #4132 holding.
- Squarepoint first reported a position in Altimmune in Q3 2016 and has held it in 22 quarters since.
- Squarepoint's Altimmune position peaked at $2.2M in Q3 2025.
- 173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.
Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.